ChainGen Bio, a Shanghai-based developer of X-oligo conjugates (XOCs), has reportedly raised RMB 45 million (USD 6.2 million) in an angel financing round co-led by Matrix Partners and Frees Fund. The proceeds will be used to advance pipeline research and development, patent layout, and company operations, including laboratory platform construction.
Company Profile and Technology
Founded in January 2022, ChainGen Bio is among China’s first domestic companies focused on developing small-molecule conjugates. The firm’s XOCs combine the targeted specificity of small nucleic acids and tissue specificity of macromolecular drugs such as antibodies, while avoiding the risk of accidental release of toxins associated with traditional antibody drug conjugates (ADCs). This innovative approach aims to enhance the safety and efficacy of targeted therapies.
Future Development Plans
ChainGen Bio has completed preclinical candidate compounds (PCCs) screening and plans to initiate Investigational New Drug (IND) filing work in 2023. The initial focus will be on rare diseases, cancer, and central nervous system diseases, positioning the company to address significant unmet medical needs in these areas.-Fineline Info & Tech
